Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SHR001
MIFTS: 53

Short Bowel Syndrome

Categories: Fetal diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Short Bowel Syndrome

About this section

MalaCards integrated aliases for Short Bowel Syndrome:

Name: Short Bowel Syndrome 12 76 53 37 55 44 15 73
Acquired Short Bowel Syndrome 12
Short Gut Syndrome 12

Classifications:

MalaCards categories:
Global: Rare diseases Fetal diseases Genetic diseases Metabolic diseases
Anatomical: Gastrointestinal diseases Liver diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:10605
MeSH 44 D012778
NCIt 50 C99059
SNOMED-CT 68 26629001
KEGG 37 H01469
UMLS 73 C0036992
Sources

Summaries for Short Bowel Syndrome

About this section
NIH Rare Diseases : 53 Short bowel syndrome is a disorder characterized by malabsorption of nutrients due to problems involving the small intestine. The small intestine is the tube-shaped organ between the stomach and large intestine, which includes the duodenum, jejunum, and ileum, where most food digestion and nutrient absorption take place. The causes of short bowel syndrome in adults include Crohn disease, mesenteric ischemia, radiation enteritis, or surgical removal of half or more of the small intestine to treat intestinal diseases or injuries. In children the main causes include necrotizing enterocolitis, intestinal atresias, and intestinal volvulus. Signs and symptoms may include diarrhea, cramping, bloating, heartburn, dehydration, malnutrition, weight loss, food sensitivities, weakness, and fatigue. Examples of treatment include diet and nutritional support, intestinal surgeries, and, in some cases, intestinal transplantation.

MalaCards based summary : Short Bowel Syndrome, also known as acquired short bowel syndrome, is related to congenital short bowel syndrome and intestinal pseudo-obstruction, and has symptoms including pain, postoperative and postoperative nausea and vomiting. An important gene associated with Short Bowel Syndrome is CLMP (CXADR Like Membrane Protein), and among its related pathways/superpathways are Signaling by GPCR and Focal Adhesion. The drugs Ursodeoxycholic acid and Lactulose have been mentioned in the context of this disorder. Affiliated tissues include liver, small intestine and colon, and related phenotypes are digestive/alimentary and growth/size/body region

Wikipedia : 76 Short bowel syndrome (SBS, or simply short gut) is a malabsorption disorder caused by a lack of... more...

Sources

Related Diseases for Short Bowel Syndrome

About this section

Diseases in the Short Bowel Syndrome family:

Congenital Short Bowel Syndrome Secondary Short Bowel Syndrome

Diseases related to Short Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
# Related Disease Score Top Affiliating Genes
1 congenital short bowel syndrome 34.3 FLNA CLMP
2 intestinal pseudo-obstruction 31.9 SST FLNA CLMP
3 dumping syndrome 29.7 SST PYY NTS GCG
4 gastrointestinal system disease 29.4 SST PYY GCG CCK
5 secondary short bowel syndrome 12.1
6 intestinal pseudoobstruction, neuronal, chronic idiopathic, x-linked 11.8
7 gastroschisis 11.3
8 liver disease 10.3
9 lactic acidosis 10.3
10 crohn's disease 10.2
11 pancreatic cystadenoma 10.2 SST GCG
12 pancreatoblastoma 10.2 SST NTS
13 vipoma 10.2 SST NTS
14 pneumatosis cystoides intestinalis 10.2 SST PYY
15 zollinger-ellison syndrome 10.2 SST NTS
16 gastrointestinal system benign neoplasm 10.2 SST GCG
17 enterocolitis 10.2
18 infantile liver failure syndrome 1 10.2
19 postcholecystectomy syndrome 10.1 SST CCK
20 perinatal necrotizing enterocolitis 10.1
21 diaphragmatic eventration 10.1 FLNA EGF
22 tsh producing pituitary tumor 10.1 TTR SST
23 duodenal gastrinoma 10.1 SST CCK
24 duodenal disease 10.1 SST CCK
25 functional gastric disease 10.1 SST CCK
26 steatorrhea 10.1 SST CCK
27 serotonin syndrome 10.1 SST PYY
28 postgastrectomy syndrome 10.1 SST PYY NTS
29 space motion sickness 10.1 NTS CCK
30 chronic ulcer of skin 10.1 TTR EGF
31 rasmussen encephalitis 10.1 SST CCK
32 diarrhea 10.1
33 pain agnosia 10.0 NTS CCK
34 pancreatic cholera 10.0 SST GCG CCK
35 acidophil adenoma 10.0 SST IGF1
36 agnosia 10.0 NTS CCK
37 pituitary infarct 10.0 SST IGF1
38 morbid obesity 10.0 PYY GCG CCK
39 hormone producing pituitary cancer 10.0 SST IGF1
40 burns 10.0 TTR HGF
41 hyperpituitarism 10.0 SST IGF1
42 cholestasis 10.0
43 encephalopathy 10.0
44 neuroendocrine tumor 10.0 SST NTS CCK
45 pituitary adenoma 1, multiple types 10.0 SST IGF1
46 endocrine pancreas disease 10.0 SST IGF1
47 donohue syndrome 10.0 IGF1 EGF
48 inflammatory bowel disease 9.9
49 thrombosis 9.9
50 nutritional deficiency disease 9.9

Graphical network of the top 20 diseases related to Short Bowel Syndrome:



Diseases related to Short Bowel Syndrome
Sources

Symptoms & Phenotypes for Short Bowel Syndrome

About this section

UMLS symptoms related to Short Bowel Syndrome:


pain, postoperative, postoperative nausea and vomiting

MGI Mouse Phenotypes related to Short Bowel Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 CLMP EGF FLNA SLC15A1 SST TTR
2 growth/size/body region MP:0005378 9.23 CLMP EGF FLNA HGF IGF1 NTS
Sources

Drugs & Therapeutics for Short Bowel Syndrome

About this section

Drugs for Short Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
2
Lactulose Approved Phase 4 4618-18-2 11333
3
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
4 Sitagliptin Phosphate Phase 4
5 Hypoglycemic Agents Phase 4,Phase 2
6 Dipeptidyl-Peptidase IV Inhibitors Phase 4
7
protease inhibitors Phase 4
8 HIV Protease Inhibitors Phase 4
9 Glucagon-Like Peptide 1 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
10 glucagon Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
11 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
12 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14
Bilirubin Phase 4,Phase 2,Phase 3 635-65-4 5280352
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Fat Emulsions, Intravenous Phase 4,Phase 2,Phase 3,Phase 1
18 Soybean oil, phospholipid emulsion Phase 4,Phase 3,Phase 2,Phase 1
19 Parenteral Nutrition Solutions Phase 4,Phase 3,Phase 2,Phase 1
20 Soy Bean Phase 4,Phase 3,Phase 2,Phase 1
21 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Incretins Phase 4,Phase 1,Phase 2,Not Applicable
23 Cholagogues and Choleretics Phase 4
24 Fibrinolytic Agents Phase 4
25 Tissue Plasminogen Activator Phase 4
26 Plasminogen Phase 4
27 Aspartic Acid Phase 4
28 alanine Phase 4,Not Applicable
29 N-Methylaspartate Phase 4
30 glutamine Phase 4,Not Applicable
31 Olive Phase 4,Phase 3
32 Phytosterol Phase 4
33
Clindamycin Approved, Vet_approved Phase 2, Phase 3 18323-44-9 29029
34
Tazobactam Approved Phase 2, Phase 3 89786-04-9 123630
35
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
36
Piperacillin Approved Phase 2, Phase 3 66258-76-2 43672
37
Ampicillin Approved, Vet_approved Phase 2, Phase 3 69-53-4 6249
38 Atosiban Approved, Investigational Phase 2, Phase 3 90779-69-4
39
Loperamide Approved Phase 3,Phase 1 53179-11-6 3955
40 Omega 3 Fatty Acid Phase 3,Phase 2,Phase 1
41 Anti-Infective Agents Phase 2, Phase 3
42 Antibiotics, Antitubercular Phase 2, Phase 3
43 Penicillanic Acid Phase 2, Phase 3
44 Clindamycin phosphate Phase 2, Phase 3
45 Antitubercular Agents Phase 2, Phase 3
46 Antiprotozoal Agents Phase 2, Phase 3
47 Gentamicins Phase 2, Phase 3
48 Piperacillin, tazobactam drug combination Phase 2, Phase 3
49 Antiparasitic Agents Phase 2, Phase 3
50 Clindamycin palmitate Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 The Use of DPP-4 Inhibitors in Short Bowel Syndrome Unknown status NCT02653131 Phase 4 Dipeptidyl peptidase-4 inhibitor
2 Short Bowel Syndrome and Teduglutide Versus Placebo Completed NCT02099084 Phase 4 Teduglutide;Placebo
3 The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients Completed NCT01974336 Phase 4 ursodeoxycholic acid
4 rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome Completed NCT02355743 Phase 4 rtPA lock therapy
5 rHGH and Intestinal Permeability in Intestinal Failure Completed NCT01380366 Phase 4 Somatropin
6 Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients Not yet recruiting NCT03562130 Phase 4 Teduglutide
7 Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS) Terminated NCT00742157 Phase 4 Growth Hormone
8 Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion Terminated NCT02476994 Phase 4 Clinolipid;Intralipid
9 Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome Withdrawn NCT01818648 Phase 4 Exenatide;Placebo
10 SMOFLipid in Patients Who Are Intralipid Intolerant Withdrawn NCT03054948 Phase 4 SMOFLipid;Standard therapy
11 Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome Completed NCT00169637 Phase 3 rhGH
12 Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition Completed NCT02682381 Phase 3 Teduglutide 0.05mg/kg;Teduglutide 0.025 mg/kg
13 Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Completed NCT00081458 Phase 3 Placebo;Teduglutide 0.05 mg/kg/d;Teduglutide 0.1 mg/kg/d
14 Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects Completed NCT00798967 Phase 3 teduglutide;placebo
15 A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Completed NCT01952080 Phase 3 teduglutide
16 Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS) Completed NCT00930644 Phase 3 teduglutide
17 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS) Completed NCT02340819 Phase 3 Teduglutide
18 Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458) Completed NCT00172185 Phase 3 teduglutide 0.05 mg/kg/d;teduglutide 0.10 mg/kg/d
19 A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021 Completed NCT01560403 Phase 3 Teduglutide
20 Impact of SPN on Infection Rate, Duration of Mechanical Ventilation & Rehabilitation in ICU Patients Completed NCT00802503 Phase 3
21 Antibiotic Safety (SCAMP) Completed NCT01994993 Phase 2, Phase 3 ampicillin and metronidazole and gentamicin;ampicillin and gentamicin and clindamycin;gentamicin and Piperacillin- tazobactam;standard of care antibiotics and metronidazole;metronidazole, clindamycin, or piperacillin-tazobactam
22 Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome Recruiting NCT03571516 Phase 3 Teduglutide
23 A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302 Recruiting NCT03268811 Phase 3 Teduglutide
24 Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support Recruiting NCT02980666 Phase 3 Teduglutide
25 Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS Recruiting NCT03690206 Phase 3 glepaglutide;Placebo
26 Cholestasis Reversal: Efficacy of IV Fish Oil Recruiting NCT00910104 Phase 2, Phase 3 Omegaven®
27 Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children Recruiting NCT01194063 Phase 3 Omega-3 fish oil lipid emulsion
28 Compassionate Use of Omegaven in Children Recruiting NCT02370251 Phase 2, Phase 3 Omegaven
29 Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies Recruiting NCT02292784 Phase 2, Phase 3 Retosiban;Atosiban;Placebo
30 Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Active, not recruiting NCT03663582 Phase 3 Teduglutide
31 Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study Active, not recruiting NCT02949362 Phase 3 Teduglutide
32 Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS) Active, not recruiting NCT02954458 Phase 3 TED
33 Safety and Efficacy Study in Infant With SBS Active, not recruiting NCT02865122 Phase 2, Phase 3 NTRA-9620;Placebo
34 An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004 Enrolling by invitation NCT03596164 Phase 3 Teduglutide
35 Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates Not yet recruiting NCT03387579 Phase 3 Lipid Emulsions, Intravenous;Intralipid, 20% Intravenous Emulsion
36 Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study Terminated NCT02266849 Phase 3 Loperamide;Placebo
37 A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals Withdrawn NCT02242656 Phase 3 Opium Tincture USP Deodorized;Opium Tincture USP Deodorized
38 A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 Withdrawn NCT02246816 Phase 3 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
39 Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease Unknown status NCT01739517 Phase 2 Omegaven Therapy
40 Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? Unknown status NCT00793195 Phase 2 Intralipid 20%;SMOFlipid 20%
41 A Phase 2 Trial Testing ZP1848 in Patients With SBS Completed NCT02690025 Phase 2 ZP1848
42 Diet/Growth Factor Mechanisms of Gut Adaptation Completed NCT00067860 Phase 2 recombinant human growth hormone
43 Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies Completed NCT01674478 Phase 2
44 Use of Pancreatic Enzymes in Short Bowel Syndrome Recruiting NCT03097029 Phase 2 Pancreatic Enzyme
45 Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support Recruiting NCT03415594 Phase 1, Phase 2 FE203799 GLP-2 analogue;FE203799 Placebo GLP-2 analogue;FE203799 GLP-2 analogue
46 Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency Recruiting NCT03408132 Phase 1, Phase 2 FE203799
47 Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS) Recruiting NCT03371862 Phase 2 Liraglutide Pen Injector [Victoza]
48 Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis Recruiting NCT02148146 Phase 1, Phase 2 Omegaven
49 Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury Recruiting NCT01845116 Phase 2 Omegaven®
50 Use of Tocofersolan (Vedrop®) to Prevent or Treat Refractive Vitamin E Deficiency in Infants and Children Not yet recruiting NCT03582384 Phase 2 Tocofersolan

Search NIH Clinical Center for Short Bowel Syndrome

Cochrane evidence based reviews: short bowel syndrome

Sources

Genetic Tests for Short Bowel Syndrome

About this section
Sources

Anatomical Context for Short Bowel Syndrome

About this section

MalaCards organs/tissues related to Short Bowel Syndrome:

41
Liver, Small Intestine, Colon, Kidney, Bone, Testes, Pancreas
Sources

Publications for Short Bowel Syndrome

About this section

Articles related to Short Bowel Syndrome:

(show top 50) (show all 1006)
# Title Authors Year
1
Developing a Novel Ambulatory Total Parenteral Nutrition-Dependent Short Bowel Syndrome Animal Model. ( 30527464 )
2019
2
Metabolic acidosis in short bowel syndrome: think D-lactic acid acidosis. ( 29769189 )
2018
3
Nutritional therapy complications in children with ultra-short bowel syndrome include growth deficiency but not cholestasis. ( 29405447 )
2018
4
What's new in short bowel syndrome? ( 29702489 )
2018
5
Energy intake in short bowel syndrome: assessment by 24-h dietary recalls compared with the doubly labelled water method. ( 29268807 )
2018
6
Chapter 5.2.1. Short Bowel Syndrome: Half a Century of Progress. ( 29596171 )
2018
7
Nutritional Therapy in Adult Short Bowel Syndrome Patients with Chronic Intestinal Failure. ( 29413019 )
2018
8
Bacteria, Bones, and Stones: Managing Complications of Short Bowel Syndrome. ( 29926935 )
2018
9
Three-dimensional CT enterography versus barium follow-through examination in measurement of remnant small intestinal length in short bowel syndrome patients. ( 29700592 )
2018
10
The protective effect of fish oil lipid emulsions on intestinal failure-associated liver disease in a rat model of short-bowel syndrome. ( 29039050 )
2018
11
Ostomy in continuity: A novel approach for the management of children with complex short bowel syndrome. ( 29602547 )
2018
12
Prophylactic cholecystectomy in short bowel syndrome: Is it being utilized? ( 29753389 )
2018
13
Duodenocolostomy as Treatment of Ileus in Short Bowel Syndrome: A Case Report. ( 29976919 )
2018
14
Congenital Short-Bowel Syndrome in an Adult Dog. ( 29310549 )
2018
15
Outcomes in patients with short bowel syndrome after autologous intestinal reconstruction: Does etiology matter? ( 29628209 )
2018
16
Innovative Discharge Process for Families with Pediatric Short Bowel Syndrome: A Prospective Nonrandomized Trial. ( 29603317 )
2018
17
Impact of Short Bowel Syndrome on Quality of Life and Family: The Patient's Perspective. ( 29532454 )
2018
18
Is Serum Methylmalonic Acid a Reliable Biomarker of Vitamin B12 Status in Children with Short Bowel Syndrome: A Case Series. ( 29129351 )
2018
19
Teduglutide for the treatment of short bowel syndrome - a safety evaluation. ( 29848084 )
2018
20
Intestinal adaptation in short bowel syndrome. What is new? ( 29974785 )
2018
21
Surgical revascularization of the celiac artery for persistent intestinal ischemia in short bowel syndrome. ( 29247810 )
2018
22
Further improvement after 24-month treatment with teduglutide in a patient with active Crohn's disease and short bowel syndrome. ( 29749341 )
2018
23
Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study. ( 29761915 )
2018
24
We Cannot Say Biologic Therapy Is Not Useful in Patients With Short-Bowel Syndrome From Resections Related to Crohn's Disease, nor Can We Conclude They Are of Value. ( 29678241 )
2018
25
Segmental reversal of distal small intestine in short bowel syndrome: a study on the influence on postoperative weight and intestinal topography in piglets. ( 29666926 )
2018
26
Duodenal lengthening in an adult with ultra-short bowel syndrome. A case report. ( 29106286 )
2018
27
Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series. ( 29603279 )
2018
28
Soluble Fiber Use in Pediatric Short Bowel Syndrome: A Survey on Prevailing Practices. ( 29767462 )
2018
29
Adult Intestinal Botulism: A Rare Presentation in an Immunocompromised Patient With Short Bowel Syndrome. ( 30225463 )
2018
30
Examining the pathophysiology of short bowel syndrome and glucagon-like peptide 2 analogue suitability in chronic intestinal failure: experience from a national intestinal failure unit. ( 30111847 )
2018
31
Retracing our STEPs: Four decades of progress in intestinal lengthening procedures for short bowel syndrome. ( 30514435 )
2018
32
Non-transplant surgical management of short bowel syndrome in children: an overview. ( 30499416 )
2018
33
Practical measurement of body composition using bioelectrical impedance, air displacement plethysmography and ultrasound in stable outpatients with short bowel syndrome receiving home parenteral nutrition: comparison of agreement between the methods. ( 30467908 )
2018
34
Measurement of Utilities Associated with Parenteral Support Requirement in Patients with Short Bowel Syndrome and Intestinal Failure. ( 30392815 )
2018
35
Surgeon's perspective on short bowel syndrome: Where are we? ( 30370230 )
2018
36
Are there differences in the growth adaptation processes of growing and mature organism models of short bowel syndrome? ( 30365828 )
2018
37
Intestinal microbiota in short bowel syndrome. ( 30342596 )
2018
38
Etiology and prognosis of pediatric short bowel syndrome. ( 30342594 )
2018
39
Short bowel syndrome (by Tom Jaksic and Biren Modi). ( 30342593 )
2018
40
Neonatal vitamin K deficiency in the son of a mother with short bowel syndrome. ( 30298697 )
2018
41
Short bowel syndrome caused by laparoscopic loop enterostomy of the jejunum in an adult with undiagnosed intestinal malrotation: A case report. ( 30290673 )
2018
42
Applications of peptide hormone ligands for the treatment of dumping and short bowel syndrome. ( 30273889 )
2018
43
A Case of Chronic Calcium Oxalate Nephropathy due to Short Bowel Syndrome and Cholecystectomy. ( 30197903 )
2018
44
Experience with teduglutide treatment for short bowel syndrome in clinical practice. ( 30145039 )
2018
45
Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome. ( 30100725 )
2018
46
Remnant Small Bowel Length in Pediatric Short Bowel Syndrome and the Correlation with Intestinal Dysbiosis and Linear Growth. ( 30077861 )
2018
47
Risk factors for parenteral nutrition-dependence and mortality with the short bowel syndrome: a 10-year retrospective study in Thailand. ( 30045420 )
2018
48
Medical and surgical management of short bowel syndrome. ( 30041905 )
2018
49
Composite Scaffolds Based on Intestinal Extracellular Matrices and Oxidized Polyvinyl Alcohol: A Preliminary Study for a New Regenerative Approach in Short Bowel Syndrome. ( 29992163 )
2018
50
Restoration of enteroendocrine and pancreatic function after internal hernia and short bowel syndrome in a young woman with gastric bypass - a 2-year follow-up. ( 29732709 )
2018
Sources

Variations for Short Bowel Syndrome

About this section
Sources

Expression for Short Bowel Syndrome

About this section
Search GEO for disease gene expression data for Short Bowel Syndrome.
Sources

Pathways for Short Bowel Syndrome

About this section

Pathways related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 66
Show member pathways
 13.35 CCK EGF FLNA GCG HGF IGF1
2
Focal Adhesion 1 37
Show member pathways
 12.5 EGF FLNA HGF IGF1
3
MAPK signaling pathway 37 1
12.29 EGF FLNA HGF IGF1
4
Proteoglycans in cancer 37
11.88 FLNA HGF IGF1
5
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.56 EGF HGF IGF1
6
Lung fibrosis 1
11.13 EGF HGF IGF1
7
Signaling events mediated by TCPTP 1
Show member pathways
 11.12 EGF HGF
8
Stabilization and expansion of the E-cadherin adherens junction 1
11.08 EGF HGF
9
Arf6 signaling events 1
10.99 EGF HGF
10
EGFR Transactivation by Gastrin 66
Show member pathways
 10.78 EGF IGF1
11
Differentiation Pathway 1
10.48 EGF HGF IGF1
Sources

GO Terms for Short Bowel Syndrome

About this section

Cellular components related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CCK EGF GCG HGF IGF1 PYY
2 platelet alpha granule lumen GO:0031093 9.33 EGF HGF IGF1
3 extracellular region GO:0005576 9.32 CCK EGF FLNA GCG HGF IGF1

Biological processes related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.95 CCK GCG NTS PYY SST
2 negative regulation of apoptotic process GO:0043066 9.84 FLNA GCG HGF IGF1
3 positive regulation of cell migration GO:0030335 9.73 EGF HGF IGF1
4 cell proliferation GO:0008283 9.67 GCG HGF IGF1 PYY
5 feeding behavior GO:0007631 9.52 GCG PYY
6 digestion GO:0007586 9.51 CCK SST
7 activation of MAPK activity GO:0000187 9.5 EGF HGF IGF1
8 positive regulation of DNA binding GO:0043388 9.49 EGF IGF1
9 positive regulation of peptidyl-threonine phosphorylation GO:0010800 9.48 EGF GCG
10 ERK1 and ERK2 cascade GO:0070371 9.46 EGF IGF1
11 platelet degranulation GO:0002576 9.46 EGF FLNA HGF IGF1
12 positive regulation of mitotic nuclear division GO:0045840 9.43 EGF IGF1
13 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.4 HGF IGF1
14 myoblast proliferation GO:0051450 9.26 HGF IGF1
15 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.26 CCK EGF HGF IGF1
16 regulation of signaling receptor activity GO:0010469 9.23 CCK GCG HGF IGF1 NTS PYY

Molecular functions related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.33 EGF HGF IGF1
2 neuropeptide hormone activity GO:0005184 9.13 CCK NTS PYY
3 hormone activity GO:0005179 9.1 CCK GCG IGF1 PYY SST TTR
Sources

Sources for Short Bowel Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....